胸部肿瘤临床试验入组标准与要求数量及复杂性持续增加
研究分析了美国东部肿瘤协作组(ECOG)1986-2016年启动的74项肺癌试验,入组标准总数与主要治疗方式、主要终点、治疗数量及启动年份相关;入组要求随时间增加仅见于药物治疗试验,血液检查筛查程序也增加,而影像、心脏评估或肺功能筛查程序未增加。
要点
- 入组标准总数与主要治疗方式相关:手术中位9条、放疗18条、药物治疗20条(p=0.02)。
- 入组标准总数随启动年份增加:1986-1995年中位16条、1996-2005年19条、2006-2016年27条(P<0.001)。
- 入组要求随时间增加仅见于药物治疗试验;血液检查筛查程序增加(p=0.05),影像、心脏评估或肺功能筛查未增加。
核心结论
- 药物治疗肺癌临床试验的入组标准和筛查程序数量持续上升,有必要继续简化方案入组要求和程序以促进试验依从性、入组、完成和普适性。
研究设计与样本
- 从东部肿瘤协作组网站识别并获取试验方案,分析其赞助或认可的胸部肿瘤临床试验。
- 共识别1986-2016年启动的74项肺癌试验。
- 入组标准按合并症(按器官系统分类)、行政要求、既往治疗和可测量疾病要求分组归类。
- 采用Kruskal-Wallis检验和Wilcoxon检验分析试验特征与入组标准之间的关联。
主要发现
- 入组标准总数与试验主要治疗相关:手术中位9条、放疗中位18条、药物治疗中位20条(p=0.02)。
- 入组标准总数与试验主要终点相关:总生存中位20条、无进展生存中位28条、其他中位17条(p=0.001)。
- 入组标准总数与治疗数量相关(p=0.05)。
- 入组标准总数与启动年份相关:1986-1995年中位16条、1996-2005年中位19条、2006-2016年中位27条(P<0.001)。
- 入组要求随时间增加仅见于药物治疗试验;血液检查筛查程序随时间增加(p=0.05),影像、心脏评估或肺功能筛查程序未增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Eligibility criteria and screening procedures are designed to optimize the scientific yield and maximize the safety of clinical trials. However, they may also heighten trial complexity, hinder enrollment, decrease generalizability, and increase costs. We analyzed the types and number of eligibility criteria and screening procedures among thoracic oncology clinical trials sponsored or endorsed by the Eastern Cooperative Oncology Group. METHODS: We identified trials and obtained protocols from the Eastern Cooperative Oncology Group website. Eligibility criteria were grouped and categorized as comorbidity (classified by organ system), administrative requirements, prior treatment, and measurable disease requirements. Associations between trial characteristics and eligibility criteria were analyzed by using the Kruskal-Wallis and Wilcoxon tests. RESULTS: A total of 74 lung cancer trials activated in 1986-2016 were identified. The total number of eligibility criteria was associated with trial principal therapy (a median of nine for surgical, 18 for radiation, and 20 for medical therapy [p = 0.02]), trial primary end point (a median of 20 for overall survival, 28 for progression-free survival, and 17 for other [p = 0.001]), number of therapies (p = 0.05), and year of activation (a median of 16 for 1986-1995, 19 for 1996-2005, and 27 for 2006-2016 [P < 0.001]). The increase in trial eligibility requirements over time was limited to medical therapy trials. Over time, there was also an increase in blood test screening procedures (p = 0.05) but not in imaging, cardiac assessment, or pulmonary function screening procedures. CONCLUSIONS: The number of eligibility criteria and screening procedures in medical therapy lung cancer clinical trials continues to rise. Continued efforts to simplify protocol eligibility and procedures are warranted to promote trial adherence, enrollment, completion, and generalizability.
引用
- Garcia S, Bisen A, Yan J, et al. Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity. J Thorac Oncol. 2017. PMID: 28802905. doi:10.1016/j.jtho.2017.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。